JY
CAPR icon

Jeff Yass’s Capricor Therapeutics CAPR Stock Holding History

Jeff Yass’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$228K Sell
9,462
-43,913
-82% -$1.33M ﹤0.01% 11673
2026
Q1 		$1.62M Sell
53,375
-24,232
-31% -$646K ﹤0.01% 6661
2025
Q4 		$2.24M Buy
77,607
+57,730
+290% +$754K ﹤0.01% 5418
2025
Q3 		$143K Sell
19,877
-26,138
-57% -$192K ﹤0.01% 11315
2025
Q2 		$457K Sell
46,015
-122,973
-73% -$1.3M ﹤0.01% 9385
2025
Q1 		$1.6M Sell
168,988
-112,314
-40% -$1.56M ﹤0.01% 6043
2024
Q4 		$3.88M Buy
281,302
+157,890
+128% +$2.77M ﹤0.01% 4002
2024
Q3 		$1.88M Buy
123,412
+82,915
+205% +$410K ﹤0.01% 5386
2024
Q2 		$193K Sell
40,497
-275,763
-87% -$1.54M ﹤0.01% 10410
2024
Q1 		$2.15M Buy
316,260
+167,145
+112% +$808K ﹤0.01% 5167
2023
Q4 		$729K Buy
149,115
+19,840
+15% +$64.6K ﹤0.01% 7765
2023
Q3 		$442K Buy
129,275
+80,640
+166% +$453K ﹤0.01% 8519
2023
Q2 		$232K Buy
48,635
+14,117
+41% +$62K ﹤0.01% 9974
2023
Q1 		$146K Sell
34,518
-94,552
-73% -$407K ﹤0.01% 10934
2022
Q4 		$498K Sell
129,070
-16,361
-11% -$78.1K ﹤0.01% 7887
2022
Q3 		$873K Sell
145,431
-24,206
-14% -$124K ﹤0.01% 6987
2022
Q2 		$592K Buy
169,637
+11,175
+7% +$39.7K ﹤0.01% 7846
2022
Q1 		$544K Sell
158,462
-56,139
-26% -$221K ﹤0.01% 8754
2021
Q4 		$629K Sell
214,601
-23,764
-10% -$83.3K ﹤0.01% 8539
2021
Q3 		$958K Sell
238,365
-42,580
-15% -$194K ﹤0.01% 7672
2021
Q2 		$1.44M Buy
280,945
+72,719
+35% +$308K ﹤0.01% 6757
2021
Q1 		$974K Buy
208,226
+26,473
+15% +$152K ﹤0.01% 7811
2020
Q4 		$623K Sell
181,753
-102,483
-36% -$444K ﹤0.01% 7805
2020
Q3 		$1.49M Buy
284,236
+165,414
+139% +$964K ﹤0.01% 5189
2020
Q2 		$547K Buy
+118,822
New +$518K ﹤0.01% 7182
2017
Q1 		– Sell
-1,432
Closed -$38K – 8983
2016
Q4 		$38K Buy
+1,432
New +$42.9K ﹤0.01% 9347
2016
Q1 		– Sell
-1,570
Closed -$48K – 9027
2015
Q4 		$48K Buy
+1,570
New +$62.5K ﹤0.01% 9106

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jeff Yass's CAPR Position: Q2 2026 in Review

Jeff Yass reduced its Capricor Therapeutics (CAPR) stake by 82% in Q2 2026, selling an estimated $1.33M and leaving 9,462 shares worth $228K. The position accounts for ﹤0.01% of the portfolio, ranked #11673.

Jeff Yass first reported a position in CAPR in Q4 2015 and has held it in 27 quarters since. The position peaked at $3.88M in Q4 2024. 169 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Jeff Yass held 9,462 shares of Capricor Therapeutics worth $228K as of Q2 2026.
  • Jeff Yass sold 43,913 Capricor Therapeutics shares in Q2 2026, an estimated $1.33M.
  • Capricor Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #11673 holding.
  • Jeff Yass first reported a position in Capricor Therapeutics in Q4 2015 and has held it in 27 quarters since.
  • Jeff Yass's Capricor Therapeutics position peaked at $3.88M in Q4 2024.
  • 169 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.